---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060453"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:04:32.093494+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biora reports Q1 net loss $4.2M, completes BT-600 dosing, results expected late Q2

## Summary
- Net loss $4.2M ($0.14/share) vs $17.4M ($1.59) in Q1 2023; operating expenses $16.1M.
- BT-600 Phase 1 trial fully dosed; SAD data showed colon delivery and lower plasma levels than oral tofacitinib.
- BioJet platform animal studies demonstrate >15% bioavailability; partnering process targeting mid-2024.
- Capital raised $19.8M new investment since Dec 2023, reduced $80M notes; $6M direct placement closed April 2024.
- Topline BT-600 data expected late June 2024; NaviCap device data presented at DDW May 19.

## SEC filing metadata
- accession: 0000950170-24-060453
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/0000950170-24-060453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/bior-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060453
- JSON: https://secwatch.observer/filing/0000950170-24-060453.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060453.txt

## Key facts
- Earnings Releases
  BIORA THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income Net loss was $4.2 million, EPS net loss per share was $0.14.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss was $4.2 million
  - EPS: net loss per share was $0.14
  - Result: reported results
  source text: Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/0000950170-24-060453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.